OXiGENE To Present at Roth Capital Partners New York Conference and The Wall Street Analyst...

Business Editors

WATERTOWN, Mass.--(BUSINESS WIRE)--Sept. 2, 2003

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a leader in the development of biopharmaceutical compounds designed to target aberrant blood vessels in solid tumors and ocular neovascular diseases, today announced its

On Wednesday, September 10, President and Chief Executive Officer Fred Driscoll will present at the Roth Capital Partners New York Conference. A live audio Webcast of the presentation will be available beginning at approximately 1:45 p.m. ET via the Company's Web site, www.oxigene.com. From the home page, follow the link under the "Investor Center" tab to "Presentations & Conference Calls."

On Monday, September 15, Mr. Driscoll will present at The Wall Street Analyst Forum's 49th NYC Analyst Conference. A live audio Webcast of this presentation will be available beginning at approximately 8:20 a.m. ET. To listen to the Webcast, go to http://www.firstcallevents.com/service/5580_Agenda1.html and click on the link that corresponds to the OXiGENE presentation.

About OXiGENE

OXiGENE is the world leader in the development of novel biopharmaceutical compounds called vascular targeting agents (VTAs), which are designed to block the flow of blood that supplies solid cancer tumors and other abnormal vasculature, while leaving healthy cells intact. OXiGENE's lead VTA, Combretastatin A4 Prodrug, has advanced into Phase II and combination clinical trials in cancer patients in the United States and Europe. The investigational compound also is being evaluated in an ophthalmic study in patients with wet age-related macular degeneration. Three other OXiGENE VTAs, OXi4503, OXi6197 and OXi8007, are in pre-clinical development. For more information about OXiGENE, visit www.oxigene.com.